Phase I, Randomized, double-blind, vehicle-controlled study to evaluate the safety, tolerability, PK and efficacy of M528101 in Healthy Volunteers and AD subjects
Latest Information Update: 29 Sep 2021
At a glance
- Drugs M 528101 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Maruho
- 29 Sep 2021 New trial record